Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389211 | 0.94 | GPR119 (0.54) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL27124574 | 0.88 | GPR119 (0.55) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL389652 | 0.87 | FAAH (0.55) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL29893530 | 0.86 | GPR119 (0.53) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL389218 | 0.86 | GPR119 (0.54) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL391706 | 0.86 | GPR119 (0.71) | GPR119FAAH | |
| SCHEMBL390534 | 0.86 | GPR119 (0.56) | GPR119FAAHSLC2A1KEAP1NFE2L2 | |
| SCHEMBL390252 | 0.85 | GPR119 (0.50) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL27035706 | 0.84 | GPR119 (0.53) | GPR119FAAHSLC2A1KDM4EPKM | |
| SCHEMBL391125 | 0.84 | GPR119 (0.48) | GPR119FAAHSLC2A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | GPR119, GCGR, GPR65 | GPR119 1/4885FAAH 579/4885SLC2A1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.